Elevated IL-13Rα2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer Initiates MAPK pathway

Inflammatory Bowel Diseases

Volumn 16, Issue 5, 2010, Pages 753-764

  Mandai, Debasmita ^a   Levine, Alan D ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Colorectal cancer; Il 13 receptor; MAP kinase; STAT6; Ulcerative colitis

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 13 RECEPTOR ALPHA2; MITOGEN ACTIVATED PROTEIN KINASE; NEUTRALIZING ANTIBODY; STAT6 PROTEIN; CYTOKINE; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

ARTICLE; CELL DENSITY; CELL DIFFERENTIATION; CELL ISOLATION; COLORECTAL CANCER; CONTROLLED STUDY; CROHN DISEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; CELL CULTURE; COLON; COLORECTAL TUMOR; CYTOLOGY; INTESTINE MUCOSA; METABOLISM; WESTERN BLOTTING;

ANTIBODIES, NEUTRALIZING; BLOTTING, WESTERN; CELLS, CULTURED; COLITIS, ULCERATIVE; COLON; COLORECTAL NEOPLASMS; CYTOKINES; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; INTESTINAL MUCOSA; MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 77950632862     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21133     Document Type: Article

References (44)

1. Chambers WM, Warren BF, Jewell DP, et al. Cancer surveillance in ulcerative colitis. Br J Surg. 2005;92: 928-936.
2. 2. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48: 526-535. (Pubitemid 32234798)
3. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454: 436-444.
4. 4. Berg DJ, Davidson N, Kuhn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest. 1996: 98: 1010-1020. (Pubitemid 26293320)
5. Rudolph U, Finegold MJ, Rich SS, et al. Ulcerative colitis and adeno-carcinoma of the colon in G alpha i2-deficient mice. Nat Genet. 1995; 10: 143-150.
6. 6. Spencer DM, Veldman GM, Banerjee S, et al. Distinct inflammatory mechanisms mediate early versus late colitis in mice. Gastroenterol-ogy. 2002;122: 94-105. (Pubitemid 34049199)
7. 7. Heller F, Fuss IJ, Nieuwenhuis EE, et al. Oxazolone colitis, a Th2 co-litis model resembling ulcerative colitis, is mediated by IL-13-produc-ing NK-T cells. Immunity. 2002;17: 629-638. (Pubitemid 35351508)
8. 8. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ul-cerative colitis. J Clin Invest. 2004; 113: 1490-1497. (Pubitemid 39071705)
9. 9. Bouma G, Strober W. The immunological and genetic basis of inflam-matory bowel disease. Nat Rev Immunol. 2003;3: 521-533. (Pubitemid 37328672)
10. Wynn TA. IL-13 effector functions. Annu Rev Immunol. 2003;21: 425-456.
11. Blanchard C, Durual S, Estienne M., et al. IL-4 and IL-13 up-regulate intestinal trefoil factor expression: requirement for STAT6 and de novo protein synthesis. J Immunol. 2004;172: 3775-3783.
12. 12. Kanai T, Watanabe M, Hayashi A, et al. Regulatory effect of interleu-kin-4 and interleukin-13 on colon cancer cell adhesion. Br J Cancer. 2000;82: 1717-1723. (Pubitemid 30229584)
13. 13. Trejdosiewicz LK, Morton R, Yang Y, et al. Interleukins 4 and 13 up-regulate expression of cd44 in human colonic epithelial cell lines. Cytokine. 1998;10: 756-765. (Pubitemid 28495226)
14. Endo Y, Marusawa H, Kou T, et al. Activation-induced cytidine de-aminase links between inflammation and the development of colitis-associated colorectal cancers. Gastroenterology. 2008;135: 889-898.
15. Kelly-Welch A, Hanson EM, Keegan AD. Interleukin-13 (IL-13) path-way. Sci STKE. 2005;2005: cm8.
16. 16. Obiri. NI, Leland P, Murata T, et al. The IL-13 receptor structure dif-fers on various cell types and may share more than one component with IL-4 receptor. J Immunol. 1997;158: 756-764. (Pubitemid 127492652)
17. 17. Miloux B, Laurent P, Bonnin O, et al. Cloning of the human IL-13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex. FEBS Lett. 1997;401: 163-166. (Pubitemid 27056108)
18. Donaldson DD, Whitters MJ, Fitz LJ, et al. The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with mu-rine IL-13 receptor alpha 1. J Immunol. 1998;161: 2317-2324.
19. 19. Wood N, Whitters MJ, Jacobson BA, et al. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J Exp Med. 2003;197: 703-709. (Pubitemid 36350865)
20. Fichtner-Feigl. S, Strober W, Kawakami K, et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-betal production and fibrosis. Nat Med. 2006;12: 99-106.
21. 21. Grossmann J, Artinger M, Grasso AW, et al. Hierarchical cleavage of focal adhesion kinase by caspases alters signal transduction during ap-optosis of intestinal epithelial cells. Gastroenterology. 2001; 120: 79-88. (Pubitemid 32061871)
22. 22. Kedar E, Ikejiri BL, Bonnard GD, et al. A rapid technique for isola-tion of viable tumor cells from solid tumors: use of the tumor cells for induction and measurement of cell-mediated cytotoxic responses. Eur J Cancer Clin Oncol. 1982;18: 991-1000. (Pubitemid 13147900)
23. Das L, Levine AD. TGF-beta inhibits IL-2 production and promotes cell cycle arrest in TCR-activated effector/memory T cells in the pres-ence of sustained TCR signal transduction. J Immunol. 2008;180: 1490-1498.
24. 24. Daines MO, Tabata Y, Walker BA, et al. Level of expression of IL-13R alpha 2 impacts receptor distribution and IL-13 signaling. J Immunol. 2006;176: 7495-7501. (Pubitemid 43849053)
25. Balkwill F, Mantovani A. Inflammation and cancer; back to Virchow? Lancet. 2001;357: 539-545.
26. Clevers H. At the crossroads of inflammation and cancer. Cell. 2004; 118: 671-674.
27. Germano G, Allavena P, Mantovani A. Cytokines as a key component of cancer-related inflammation. Cytokine. 2008;43: 374-379.
28. Spencer DM, Levine AD. Neutralizing IL-4 or IL-13 alters mucosal immunity in late phase colitis of IL-10-/- mice. FASEB J. 2003;17: C-230.
29. 29. Heller F, Florian P, Bojarski. C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129: 550-564. (Pubitemid 41096643)
30. 30. Wongpiyabovorn J, Suto H, Ushio H, et al. Up-regulation of interleu-kin-13 receptor alpha 1 on human keratinocytes in the skin of psoriasis and atopic dermatitis. J Dermatol Sci. 2003;33: 31-40 (Pubitemid 37188475)
31. 31. Ohshima K, Akaiwa M, Umeshita R, et al. Interleukin-13 and interleu-kin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis. Histopathology. 2001;38: 368-375. (Pubitemid 34225031)
32. Mintz A, Gibo DM, Slagle-Webb B, et al. IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia. 2002;4: 388-399.
33. 33. Kawakami M, Kawakami K, Kasperbauer JL, et al. Interleukin-13 re-ceptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker. Clin Cancer Res. 2003;9: 6381-6388. (Pubitemid 38031823)
34. 34. Mudter J, Weigmann B, Bartsch B, et al. Activation pattern of signal transducers and activators of transcription (STAT) factors in inflam-matory bowel diseases. Am J Gastroenterol. 2005;100: 64-72. (Pubitemid 41623270)
35. 35. Klampfer L. The role of signal transducers and activators of transcrip-tion, in colon cancer. Front Biosci. 2008;13: 2888-2899. (Pubitemid 351589205)
36. Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and ac-tivator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002;99: 618-626.
37. 37. Das S, Roth CP, Wasson. LM, et al. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Prostate. 2007;67: 1550-1564. (Pubitemid 47536154)
38. 38. Zhang M, Zhou Y, Xie C, et al. STAT6 specific shRNA inhibits pro-liferation and induces apoptosis in colon cancer HT-29 cells. Cancer Lett. 2006;243: 38-46. (Pubitemid 44485318)
39. 39. David M, Ford D, Bertoglio J, et al. Induction of the IL-13 receptor alpha2-chain by IL-4 and IL-13 in human keratinocytes: involvement of STAT6, ERK and p38 MAPK pathways. Oncogene. 2001 ;20: 6660-6668. (Pubitemid 33020595)
40. 40. Van Den Blink B, Ten Hove T, Van Den Brink GR, et al. From extracellular to intracellular targets, inhibiting MAP kinases in treat-ment of Crohn's disease. Ann N Y Acad Sci. 2002;973: 349-358. (Pubitemid 36125034)
41. Fang JY, Richardson BC. The MAPK signalling pathways and colo-rectal cancer. Lancet Oncol. 2005;6: 322-327.
42. 42. Atherton HC, Jones G, Danahay H. IL-13-induced changes in the gob-let cell density of human bronchial epithelial cell cultures: MAP ki-nase and phosphatidylinositol 3-kinase regulation. Am J Physiol Lung Cell Mol Physiol. 2003;285: L730-739. (Pubitemid 37022875)
43. 43. Fujisawa T, Ide K, Holtzman MJ, et al. Involvement of the p38 MAPK pathway in IL-13-induced mucous cell metaplasia in mouse tracheal epithelial cells. Respirology. 2008;13: 191-202. (Pubitemid 351388781)
44. 44. Hashimoto S, Gon Y, Takeshita I, et al. IL-4 and IL-13 induce myofi-broblastic phenotype of human lung fibroblasts through c-Jun NH2-terminal kinase-dependent pathway. J Allergy Clin Immunol. 2001; 107: 1001-1008. (Pubitemid 32523339)